Taysha Gene Therapies Inc.

TSHA
$6.45 (+ $0.26 + 4.20%)
Last updated: 2026-08-19 14:49 UTC
TSHA Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS8776191061
CUSIP877619106
Market Price6.45
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.33
Market Cap$1.6B
Book Value0.8
Price to Book7.297
Beta-0.63
52w High6.02
52w Low1.05
Next Earnings DateN/A

Taysha Gene Therapies Inc. trades under ticker TSHA on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US8776191061, CUSIP 877619106. Also searched as Taysha Gene Therapies.

Related researchTSHA stock priceTSHA share price877619106Taysha Gene Therapies stockTaysha Gene Therapies share price
About the Company
Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effective treatment options. Taysha Gene Therapies is committed to leveraging its expertise in gene therapy to create long-term, potentially curative solutions that improve patient outcomes. It collaborates with academic institutions and utilizes strategic partnerships to facilitate the advancement and commercialization of its pipeline. Through targeted delivery systems and innovative genetic approaches, Taysha focuses on various therapeutic candidates, aiming to address a wide spectrum of CNS disorders. Positioned prominently in the biotechnology sector, the company plays a significant role in advancing the field of genetic medicine, offering hope for patients with limited options. Its contributions help to shape the future of precision medicine, marking a pivotal shift in the treatment landscape for genetic disorders.
Price History